Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Maertens

Showing results (241-250 of 361) with videos related to

Pageof 37
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2018
Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow TransplantationSimone Cesaro, Gloria Tridello, Nicole Blijlevens, et al.
American Journal of Hematology|December 6, 2025
Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMTArnon Nagler, Sarah Kayser, Allain Thibeault Ferhat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2021
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical TrialRobin K Avery, Sophie Alain, Barbara D Alexander, et al.
American Journal of Hematology|May 30, 2025
Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWPAli Bazarbachi, Jacques-Emmanuel Galimard, Iman Abou Dalle, et al.
Leukemia|February 5, 2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMTJordi Esteve, Sebastian Giebel, Myriam Labopin, et al.
The New England Journal of Medicine|September 25, 2009
High-dose daunorubicin in older patients with acute myeloid leukemiaBob Löwenberg, Gert J Ossenkoppele, Wim van Putten, et al.
Nature Communications|June 19, 2021
Serum amyloid P component is an essential element of resistance against Aspergillus fumigatusAndrea Doni, Raffaella Parente, Ilaria Laface, et al.
Blood|September 10, 2015
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantationChristoph Schmid, Myriam Labopin, Gerard Socié, et al.
Bone Marrow Transplantation|October 16, 2025
Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registryArnon Nagler, Jordi Esteve, Jacques-Emmanuel Galimard, et al.
Eclinicalmedicine|April 12, 2021
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipientsPer Ljungman, Arancha Bermudez, Aaron C Logan, et al.
Pageof 37

Showing results (241-250 of 361) with videos related to

Sort By:
Pageof 37
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2018
Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow TransplantationSimone Cesaro, Gloria Tridello, Nicole Blijlevens, et al.
American Journal of Hematology|December 6, 2025
Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMTArnon Nagler, Sarah Kayser, Allain Thibeault Ferhat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2021
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical TrialRobin K Avery, Sophie Alain, Barbara D Alexander, et al.
American Journal of Hematology|May 30, 2025
Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWPAli Bazarbachi, Jacques-Emmanuel Galimard, Iman Abou Dalle, et al.
Leukemia|February 5, 2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMTJordi Esteve, Sebastian Giebel, Myriam Labopin, et al.
The New England Journal of Medicine|September 25, 2009
High-dose daunorubicin in older patients with acute myeloid leukemiaBob Löwenberg, Gert J Ossenkoppele, Wim van Putten, et al.
Nature Communications|June 19, 2021
Serum amyloid P component is an essential element of resistance against Aspergillus fumigatusAndrea Doni, Raffaella Parente, Ilaria Laface, et al.
Blood|September 10, 2015
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantationChristoph Schmid, Myriam Labopin, Gerard Socié, et al.
Bone Marrow Transplantation|October 16, 2025
Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registryArnon Nagler, Jordi Esteve, Jacques-Emmanuel Galimard, et al.
Eclinicalmedicine|April 12, 2021
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipientsPer Ljungman, Arancha Bermudez, Aaron C Logan, et al.
Pageof 37